Common Contracts
2 similar License Agreement contracts by Biodelivery Sciences International Inc
Confidential Treatment Requested by BioDelivery Sciences International, Inc. Confidential treatment requested with respect to certain portions hereof denoted with LICENSE AGREEMENTLicense Agreement • March 30th, 2018 • Biodelivery Sciences International Inc • Pharmaceutical preparations • New York
This License Agreement (“Agreement”) is made as of July 12, 2017 (the “Effective Date”) by and between BioDelivery Sciences International, Inc., a Delaware corporation with its principal offices at 4131 Parklake Avenue, Suite 225, Raleigh, North Carolina 27612 (“Parent”), its wholly-owned subsidiary Arius Pharmaceuticals, Inc., a Delaware corporation with an office at the same address (“Arius”, and together with Parent, “BDSI”), and Purdue Pharma, an Ontario limited partnership with its principal office at 575 Granite Court, Pickering, ON Canada L1W 3W8 (“Purdue”). BDSI and Purdue are sometimes referred to collectively herein as the “Parties” or singly as a “Party.”
LICENSE AGREEMENTLicense Agreement • November 9th, 2017 • Biodelivery Sciences International Inc • Pharmaceutical preparations • New York
This License Agreement (“Agreement”) is made as of July 12, 2017 (the “Effective Date”) by and between BioDelivery Sciences International, Inc., a Delaware corporation with its principal offices at 4131 Parklake Avenue, Suite 225, Raleigh, North Carolina 27612 (“Parent”), its wholly-owned subsidiary Arius Pharmaceuticals, Inc., a Delaware corporation with an office at the same address (“Arius”, and together with Parent, “BDSI”), and Purdue Pharma, an Ontario limited partnership with its principal office at 575 Granite Court, Pickering, ON Canada L1W 3W8 (“Purdue”). BDSI and Purdue are sometimes referred to collectively herein as the “Parties” or singly as a “Party.”
